Product Description
Mechanisms of Action: Gene Therapy, SMN1
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hangzhou Jiayin Biotech Ltd
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Muscular Atrophy, Spinal|Spinal Muscular Atrophies of Childhood
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06888661 |
EXG001-307-011 | P1 |
Enrolling by invitation |
Muscular Atrophy, Spinal |
2026-03-01 |
50% |
2025-03-22 |
Primary Endpoints|Treatments |
NCT05614531 |
EXG001-307-102 | P2 |
Enrolling by invitation |
Muscular Atrophy, Spinal|Spinal Muscular Atrophies of Childhood |
2025-08-01 |
12% |
2024-09-20 |
Primary Endpoints |
NCT06576388 |
EXG001-307-101 | P1 |
Completed |
Spinal Muscular Atrophies of Childhood|Muscular Atrophy, Spinal |
2023-09-21 |
2024-08-29 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|